Institute for Cancer Research

 

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

Harald Stenmark<br>Inst. Head
Harald Stenmark
Inst. Head

Scientific production - Institute for Cancer Research

  Publications Doctoral theses
2017 so far  
 2016 235  15
2015 221 21
2014 174 25

Annual report 2015 (pdf format)

 

Latest news

CCB researchers uncover novel mechanism of cellular metabolic control

 
First author Zhi Hong (left) and last author Camilla Raiborg
First author Zhi Hong (left) and last author Camilla Raiborg

A protein kinase complex known as mTORC1 is known to control cell growth by upregulating anabolic processes and downregulating catabolism in response to growth factors and nutritional cues such as amino acids. Because mTORC1 signalling is an important driver of cancer development, we need to understand how this signalling is regulated.
mTORC1 signalling occurs from lysosome membranes and is regulated by the lipid kinase PIK3C3 and its catalytic product, phosphatidylinositol 3-phosphate (PI3P), but the mechanism has remained unknown. Now, postdoc Zhi Hong and her co-workers in Camilla Raiborg’s project group at the Department of Molecular Cell Biology at the Institute for Cancer Research have discovered that PIK3C3 and PI3P control mTORC1 activation by regulating lysosome positioning.

 
 

Breast cancer research highlighted by the Norwegian Cancer Society:

New additional treatment for breast cancer patients

 
Olav Engebråten
Olav Engebråten

The Norwegian Cancer Society present research they support regularly, in a popular science form.
Olav Engebråten from the Department of Oncology at OUH has recently (October 10th) been interviewed about The NeoAva study he is leading - a clinical breast cancer study for patients with tumors more than 2.5 cm in diameter, where treatment with bevacizumab is involved - a substance (antibody) that binds and removes one of the factors (VEGF) excreted from the cancer cells that may stimulate the growth of blood vessels. The treatment can therefore prevent blood vessels from growing into the tumor tissue, and enhance the effect of the chemotherapy in the tumor.

 
 

Induced pluripotent stem cell research featured on Norwegian national news broadcast

 
Mathias Toft during NRK interview
Mathias Toft during NRK interview

A project involving the generation of induced pluripotent stem cells (iPSCs) from Norwegian patients with Parkinsons disease was recently featured on the evening news broadcast from the Norwegian Broadcasting Corporation (NRK). This project - a collaboration between neurologist Mathias Toft, project group leader at the Department of Neurology at Oslo University Hospital and Gareth Sullivan, group leader at the Stem Cell Center - aims to generate neurons from the patient-derived iPS cells and to investigate disease mechanisms in these. The project is an example of the activities supported by The Neuron Factory platform at the Norwegian Center for Stem Cell Research.

 
 

Tor Inge Tønnessen "Researcher of the Month" for September

 
T.I. Tønnessen
T.I. Tønnessen

The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) has appointed Tor Inge Tønnessen from the Anaesthesia & Intensive Care Research Group at the Division of Emergencies and Critical Care at Oslo University Hospital as "Researcher of the month" for the month of September 2017.

 
 

Collaboration to identify novel biomarkers that can predict whether a patient will respond positively to pembrolizumab

 

The Norwegian bioinformatics company OncoImmunity and the Norwegian Cancer Genomics Consortium (NCGC) at Oslo University Hospital announce September 20th that they have entered into a collaboration with the American "Sarcoma Alliance for Research through Collaboration" (SARCtrials.org), to search for active neoantigens and related immune biomarker signatures of response in an American clinical trial on sarcoma patients treated with the PD1 immune checkpoint inhibitor pembrolizumab.

 
 

Sept 29th - Information day about EMBL, EMBO and HSPF:

Scientific opportunities in Europe

 

This event is open to all, and is designed to help inform Norwegian scientists about the training opportunities, services and infrastructure available at the EMBL (European Molecular Biology Laboratory). The meeting is sponsored by the EMBL Alumni Association, and has received funding from UiO: Life Science and the Research Council of Norway.  
Date & Time: 9am-6pm, Friday 29 September 2017
Location: University Library Auditorium 1, Georg Sverdrup Hus, Blindern, University of Oslo.